Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Jon C. Ogg | Aug 16, 2016 at 9:55 AM EDT

Why Every Analyst in the World Loves Patheon Even After a Strong IPO

Patheon saw its quiet period come to an end on Monday, and the analyst floodgates opened wide. What stood out…

Chris Lange | Aug 16, 2016 at 9:05 AM EDT

Can Eleven Biotherapeutics Keep Climbing With This Roche Deal?

Eleven Biotherapeutics is continuing to rise this week after the company announced the effectiveness of the exclusive licensing deal with…

Jon C. Ogg | Aug 15, 2016 at 1:05 PM EDT

Credit Suisse Issues Top Pharma Picks in Bull/Bear Upside Analysis

Credit Suisse has run bullish and bearish scenarios for what the firm feels is a reasonable upside and downside for…

Chris Lange | Aug 15, 2016 at 10:40 AM EDT

Why Aurinia Pharma Is Getting Slaughtered

Shares of Aurinia Pharmaceuticals were halved early in Monday’s session following a mid-stage trial hiccup.

Lee Jackson | Aug 12, 2016 at 9:45 AM EDT

3 Top Health Care REITs Are Still Paying Outstanding Dividends

One sector that continues to grow is health care, and the health care real estate investment trusts that have traded…

Lee Jackson | Aug 12, 2016 at 8:25 AM EDT

Why This Analyst Sees Huge Upside for Valeant and 2 More Specialty Pharmas

All three of these specialty pharmaceutical stocks come with a fair share of risk but provide big upside potential as…

Chris Lange | Aug 11, 2016 at 1:05 PM EDT

5 Biohealth Stocks Rising 10% or More on News

A few biohealth companies made absolutely massive runs in Thursday’s session. The companies 24/7 Wall St. has picked stood out…

Lee Jackson | Aug 11, 2016 at 8:20 AM EDT

Why Jefferies Sees 3 Big Biotechs Having Key Upside Catalysts Coming

Investors are now focusing on fundamentals and near-term catalysts that could provide a tailwind for some of the biotech leaders.

Jon C. Ogg | Aug 10, 2016 at 2:25 PM EDT

Two Polar Opposite Views on GW Cannabinoid Drug Upside

GW Pharmaceuticals PLC (NASDAQ: GWPH) was seeing some selling pressure after the company reported earnings. Its third quarter loss was actually…

Jon C. Ogg | Aug 10, 2016 at 10:20 AM EDT

Why Analysts Are Abandoning Myriad Genetics Upside Hopes

24/7 Wall St. could not help but notice how many analysts on Wall Street have simply abandoned their old upside…

Chris Lange | Aug 10, 2016 at 9:05 AM EDT

Major Pharma Short Interest Slides

The July 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical…

Chris Lange | Aug 10, 2016 at 8:50 AM EDT

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the July 29 settlement date and short interest decreased across these selected biotech…

Chris Lange | Aug 9, 2016 at 12:35 PM EDT

What to Expect When Mylan Reports Earnings

Mylan is expected to release its second-quarter financial results after the markets close on Tuesday.

Lee Jackson | Aug 9, 2016 at 11:05 AM EDT

3 Biotech Stocks With Catalysts That Have 90% to 500% Upside Potential

The analysts at Stifel have noted three biotech companies that not only have data that could prove to be huge,…

Chris Lange | Aug 9, 2016 at 9:05 AM EDT

Is This Earnings Report the Start of the Valeant Turnaround?

Valeant Pharmaceuticals International appears to have a turnaround underway, after the company reported its second-quarter financial results before the markets…

1 … 198 199 200 201 202 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Why Every Analyst in the World Loves Patheon Even After a Strong IPO

Can Eleven Biotherapeutics Keep Climbing With This Roche Deal?

Credit Suisse Issues Top Pharma Picks in Bull/Bear Upside Analysis

Why Aurinia Pharma Is Getting Slaughtered

3 Top Health Care REITs Are Still Paying Outstanding Dividends

Why This Analyst Sees Huge Upside for Valeant and 2 More Specialty Pharmas

5 Biohealth Stocks Rising 10% or More on News

Why Jefferies Sees 3 Big Biotechs Having Key Upside Catalysts Coming

Two Polar Opposite Views on GW Cannabinoid Drug Upside

Why Analysts Are Abandoning Myriad Genetics Upside Hopes

Major Pharma Short Interest Slides

Short Sellers Run for Cover From Major Biotechs

What to Expect When Mylan Reports Earnings

3 Biotech Stocks With Catalysts That Have 90% to 500% Upside Potential

Is This Earnings Report the Start of the Valeant Turnaround?

Everyone’s Talking About Uber. Smart Money Is Watching Grab’s Profitability Inflection Instead

The Roth 401(k) Switch Pre-Retirees Are Making at 60 to Lock In Tax-Free Income for Life

China’s hold over the physical silver market looms large for 2026

The Roth 401(k) Switch Pre-Retirees Are Making at 60 to Lock In Tax-Free Income for Life

The Social Security Tax Torpedo: How One IRA Withdrawal Can Cost $5,000

Everyone’s Talking About Uber. Smart Money Is Watching Grab’s Profitability Inflection Instead

The Roth 401(k) Switch Pre-Retirees Are Making at 60 to Lock In Tax-Free Income for Life

Health and Healthcare Articles

All Health and Healthcare Articles

Why Every Analyst in the World Loves Patheon Even After a Strong IPO

Can Eleven Biotherapeutics Keep Climbing With This Roche Deal?

Credit Suisse Issues Top Pharma Picks in Bull/Bear Upside Analysis

Why Aurinia Pharma Is Getting Slaughtered

3 Top Health Care REITs Are Still Paying Outstanding Dividends

Why This Analyst Sees Huge Upside for Valeant and 2 More Specialty Pharmas

5 Biohealth Stocks Rising 10% or More on News

Why Jefferies Sees 3 Big Biotechs Having Key Upside Catalysts Coming

Two Polar Opposite Views on GW Cannabinoid Drug Upside

Why Analysts Are Abandoning Myriad Genetics Upside Hopes

Major Pharma Short Interest Slides

Short Sellers Run for Cover From Major Biotechs

What to Expect When Mylan Reports Earnings

3 Biotech Stocks With Catalysts That Have 90% to 500% Upside Potential

Is This Earnings Report the Start of the Valeant Turnaround?

Everyone’s Talking About Uber. Smart Money Is Watching Grab’s Profitability Inflection Instead

The Roth 401(k) Switch Pre-Retirees Are Making at 60 to Lock In Tax-Free Income for Life

China’s hold over the physical silver market looms large for 2026

Featured Reads

The Roth 401(k) Switch Pre-Retirees Are Making at 60 to Lock In Tax-Free Income for Life

The Social Security Tax Torpedo: How One IRA Withdrawal Can Cost $5,000